{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:41:23Z","timestamp":1760136083331,"version":"build-2065373602"},"reference-count":54,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Predictive biomarkers are crucial in clarifying the best strategy to use poly(ADP-ribose) polymerase inhibitors (PARPi) for the greatest benefit to ovarian cancer patients. PARPi are specifically lethal to cancer cells that cannot repair DNA damage by homologous recombination (HR), and HR deficiency is frequently associated with BRCA1\/2 mutations. Genetic tests for BRCA1\/2 mutations are currently used in the clinic, but results can be inconclusive due to the high prevalence of rare DNA sequence variants of unknown significance. Most tests also fail to detect epigenetic modifications and mutations located deep within introns that may alter the mRNA. The aim of this study was to investigate whether quantitation of BRCA1\/2 mRNAs in ovarian cancer can provide information beyond the DNA tests. Using the nCounter assay from NanoString Technologies, we analyzed RNA isolated from 38 ovarian cancer specimens and 11 normal fallopian tube samples. We found that BRCA1\/2 expression was highly variable among tumors. We further observed that tumors with lower levels of BRCA1\/2 mRNA showed downregulated expression of 12 additional HR genes. Analysis of 299 ovarian cancer samples from The Cancer Genome Atlas (TCGA) confirmed the coordinated expression of BRCA1\/2 and HR genes. To facilitate the routine analysis of BRCA1\/2 mRNA in the clinical setting, we developed a targeted droplet digital PCR approach that can be used with FFPE samples. In conclusion, this study underscores the potential clinical benefit of measuring mRNA levels in tumors when BRCA1\/2 DNA tests are negative or inconclusive.<\/jats:p>","DOI":"10.3390\/biomedicines10020199","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T08:09:20Z","timestamp":1642493360000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1\/2 and Homologous Recombination Genes"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9230-9870","authenticated-orcid":false,"given":"No\u00e9lia","family":"Cust\u00f3dio","sequence":"first","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8367-2317","authenticated-orcid":false,"given":"Rosina","family":"Savisaar","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-595X","authenticated-orcid":false,"given":"C\u00e9lia","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8108-6285","authenticated-orcid":false,"given":"Pedro","family":"Bak-Gordon","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]},{"given":"Maria I.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]},{"given":"Joana","family":"Tavares","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica, Hospital de Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte, 1649-028 Lisboa, Portugal"}]},{"given":"Paula B.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Hospital CUF Descobertas, 1998-018 Lisboa, Portugal"},{"name":"Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]},{"given":"Ana","family":"Peixoto","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gen\u00e9tica, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"given":"Carla","family":"Pinto","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gen\u00e9tica, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4894","authenticated-orcid":false,"given":"Carla","family":"Escudeiro","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gen\u00e9tica, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5982","authenticated-orcid":false,"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gen\u00e9tica, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}]},{"given":"Maria","family":"Carmo-Fonseca","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2019). SEER Cancer Statistics Review, 1975\u20132016, National Cancer Institute. Based on November 2018 SEER Data Submission."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Network","year":"2011","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: Different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00439-017-1809-4","article-title":"Deep intronic mutations and human disease","volume":"136","year":"2017","journal-title":"Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/ncomms4361","article-title":"Genome-wide transcriptome profiling of homologous recombination DNA repair","volume":"5","author":"Peng","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.biochem.76.050106.093909","article-title":"The nonsense-mediated decay RNA surveillance pathway","volume":"76","author":"Chang","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15943","DOI":"10.1038\/ncomms15943","article-title":"A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay","volume":"8","author":"Hu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.tibtech.2018.12.002","article-title":"The Ultimate qPCR Experiment: Producing Publication Quality, Reproducible Data the First Time","volume":"37","author":"Taylor","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1373\/clinchem.2013.206375","article-title":"The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1086\/346173","article-title":"A note on calculation of empirical P values from Monte Carlo procedure","volume":"72","author":"North","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: A Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Papp","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","article-title":"The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells","volume":"37","author":"Hu","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nbt1385","article-title":"Direct multiplexed measurement of gene expression with color-coded probe pairs","volume":"26","author":"Geiss","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1093\/nar\/27.22.4436","article-title":"Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples","volume":"27","author":"Masuda","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"von Ahlfen, S., Missel, A., Bendrat, K., and Schlumpberger, M. (2007). Determinants of RNA quality from FFPE samples. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0001261"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/ng.3664","article-title":"The rules and impact of nonsense-mediated mRNA decay in human cancers","volume":"48","author":"Lindeboom","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/cge.12441","article-title":"The role of targeted BRCA1\/BRCA2 mutation analysis in hereditary breast\/ovarian cancer families of Portuguese ancestry","volume":"88","author":"Peixoto","year":"2015","journal-title":"Clin. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.2006.06.9443","article-title":"Screening for a BRCA2 rearrangement in high-risk breast\/ovarian cancer families: Evidence for a founder effect and analysis of the associated phenotypes","volume":"25","author":"Machado","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17334","DOI":"10.18632\/oncotarget.24671","article-title":"Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and\/or ovarian cancer","volume":"9","author":"Caputo","year":"2018","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ymeth.2012.09.012","article-title":"Droplet Digital\u2122 PCR quantitation of HER2 expression in FFPE breast cancer samples","volume":"59","author":"Heredia","year":"2013","journal-title":"Methods"},{"key":"ref_35","first-page":"606","article-title":"HER2 mRNA transcript quantitation in breast cancer","volume":"19","author":"Meehan","year":"2017","journal-title":"Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex."},{"key":"ref_36","first-page":"717","article-title":"Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells","volume":"7","author":"Gudas","year":"1996","journal-title":"Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1006\/dbio.1997.8526","article-title":"Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues","volume":"184","author":"Rajan","year":"1997","journal-title":"Dev. Biol."},{"key":"ref_38","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molcel.2010.12.005","article-title":"miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors","volume":"41","author":"Moskwa","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR Signaling in Cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2010.01.019","article-title":"AKT regulates BRCA1 stability in response to hormone signaling","volume":"319","author":"Nelson","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR Pathway Causes Drug Resistance in Breast Cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/s41598-017-02217-x","article-title":"Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: From variable nonsense to publication quality data","volume":"7","author":"Taylor","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wang, L., Wei, J., Qian, X., Yin, H., Zhao, Y., Yu, L., Wang, T., and Liu, B. (2008). ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and\/or docetaxel. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-97"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-07-1083","article-title":"BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy","volume":"13","author":"Quinn","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ygyno.2011.08.017","article-title":"BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer","volume":"123","author":"Carser","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gao, Y., Zhu, J., Zhang, X., Wu, Q., Jiang, S., Liu, Y., Hu, Z., Liu, B., and Chen, X. (2013). BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy\/chemoradiotherapy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0052589"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.3892\/ol.2016.4546","article-title":"Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report","volume":"11","author":"Huang","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Rosell, R., Perez-Roca, L., Sanchez, J.J., Cobo, M., Moran, T., Chaib, I., Provencio, M., Domine, M., Sala, M.A., and Jimenez, U. (2009). Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005133"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/hmg\/ddh260","article-title":"BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer","volume":"13","author":"Taron","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41416-018-0217-4","article-title":"BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer","volume":"119","author":"Tsibulak","year":"2018","journal-title":"Br. J. Cancer"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/2\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:03:19Z","timestamp":1760133799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/2\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["biomedicines10020199"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10020199","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}